Challenges and Opportunities in New Drug Development
In the 18th century, mercury was the treatment of choice for syphilis.1 Mercury was so commonly used, in fact, that physicians rarely saw a patient who had not taken it, even though it was eventually proven ineffective.2 As a result, it was virtually impossible to separate the effects of the disease from the treatment. Many physicians even insisted that mercury had no toxic effects.
KeywordsDrug Development Drug Selection Adrenocortical Carcinoma Nitrogen Mustard Modern Chemotherapy
Unable to display preview. Download preview PDF.
- 1.Mathias A. The Mercurial Disease: an inquiry into the history and nature of the disease produced in the human condition by the use of mercury. 3rd ed. London: J. Callow, 1866.Google Scholar
- 2.Goldwater LJ. Mercury: a History of Quicksilver. Baltimore: York Press, 1972.Google Scholar
- 3.Hacker MP, Lazo JS, Tritton TR. Organ directed toxicities of anticancer drugs. Boston: Martinus Nijhoff Publishing, 1987.Google Scholar
- 5.Perry MC, Yarbro JW. Toxicity of chemotherapy. Orlandlo: Grune and Stratton, 1984.Google Scholar
- 13.Von Hoff DD, Casper J, Bradley E et al. Association between human tumor colony forming assay results and response of an individual patient’s tumor to chemotherapy. Am J Med 1981; 70: 1047.Google Scholar
- 14.Von Hoff DD, Clark GM, Stogdill BJ et al. Prospective clinical trial of a human tumor cloning system. Cancer Res 1983; 3: 1926–31.Google Scholar
- 15.Boyd MR, Paull KD, Rubinstein LR. Data display and analysis strategies for the NCI disease-oriented in vitro antitumor drug screen. In: Valeriote FA, Corbett T, Baker L, eds. Cytotoxic anticancer drugs: models and concepts for drug discovery and development. Amsterdam: Kulwer Academic Publishers, 1992; 11–34.CrossRefGoogle Scholar
- 16.Boyd MR. The future of new drug development. In: Niederhubr JE, ed. Current therapy in oncology. Philadelphia: BC Decker Inc., 1993; 11–22.Google Scholar
- 17.Grever MR, Hollingshead MG, Alley MC et al. Status of in vivo evaluations in the NCI anticancer drug discovery program. Proc Am Assoc Cancer Res 1994; 35: 369.Google Scholar
- 23.Boyd MR. Status of the NCI preclinical antitumor drug discovery screen. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principle and practice of oncology updates. Philadelphia: JP Lippincott, 1989; 3: 1–12.Google Scholar